Bladder Cancer

Andrew T. Lenis; Patrick M. Lec; Karim Chamie; MSHS MD

doi:10.1001/jama.2020.17598

Abstract

Improved understanding of the molecular biology and genetics of bladder cancer has evolved the way localized and advanced disease is diagnosed and treated. While intravesical BCG has remained the mainstay of therapy for intermediate and high-risk non-muscle-invasive bladder cancer, the therapeutic options for muscle-invasive and advanced disease has expanded to include immunotherapy with checkpoint inhibition, targeted therapies, and antibody-drug conjugates.

Keywords

MedicineBladder cancerCystoscopyCystectomyMalignancyCancerDiseaseOncologyRadiation therapyPopulationImmunotherapyInternal medicineUrinary system

MeSH Terms

AdministrationIntravesicalAntineoplastic AgentsBCG VaccineCombined Modality TherapyCystectomyCystoscopyFemaleHumansImmunotherapyMaleMutationNeoplasm InvasivenessRisk FactorsUrinary BladderUrinary Bladder Neoplasms

Affiliated Institutions

University of California, Los Angeles US

Related Publications

European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)

Marko Babjuk , Maximilian Burger , Otakar Čapoun +14 more

The European Association of Urology (EAU) has released an updated version of the guidelines on non-muscle-invasive bladder cancer (NMIBC). To present the 2021 EAU guidelines on ...

2021 European Urology 1420 citations

Treatment of muscle‐invasive and advanced bladder cancer in 2020

Vaibhav G. Patel , William Oh , Matthew D. Galsky

Abstract Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades, the systemic management of muscle‐invasive and advanced bladder cancer has pri...

2020 CA A Cancer Journal for Clinicians 1092 citations

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines

J. Alfred Witjes , Harman Max Bruins , Richard Cathomas +12 more

This overview presents the updated European Association of Urology (EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). To provide practical evidence-base...

2020 European Urology 2051 citations

Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.

Three cycles of neoadjuvant chemotherapy before cystectomy or radiotherapy did not give the 10% improvement in 3-year survival that was judged to be necessary for introduction i...

1999 PubMed 162 citations

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

Thomas Powles , Se Hoon Park , Éric Voog +24 more

Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who h...

2020 New England Journal of Medicine 1374 citations

Publication Info

Year: 2020
Type: review
Volume: 324
Issue: 19
Pages: 1980-1980
Citations: 1621
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Bladder Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1621

OpenAlex

Influential

1307

CrossRef

Cite This

APA Style

                            
                                
                                    Andrew T. Lenis, 
                                
                                    Patrick M. Lec, 
                                
                                    Karim Chamie
                                
                                et al.
                            
                            (2020). 
                            Bladder Cancer. 
                            JAMA
                            , 324
                            (19)
                            , 1980-1980.
                            https://doi.org/10.1001/jama.2020.17598
                        

Identifiers

DOI: 10.1001/jama.2020.17598
PMID: 33201207

Data Quality

Data completeness: 81%